srage  (R&D Systems)

Journal: BMJ Open Respiratory Research

Article Title: Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome

doi: 10.1136/bmjresp-2025-003630

Figure Lengend Snippet: Plasma sRAGE and Ang-2 levels stratified by PARDS severity Comparison was made between mild, moderate and severe PARDS versus control using the Mann-Whitney U test. P values are subjected to Bonferroni correction for multiple testing. Ang-2, angiopoietin-2; PARDS, paediatric acute respiratory distress syndrome; sRAGE, soluble receptor for advanced glycation end-products.

Article Snippet: The plasma was then aspirated and stored at −80°C for later batched analysis. sRAGE (R&D Systems; catalogue no. DY1145) and Ang-2 (R&D Systems; catalogue no. DY623) were measured in duplicate using an ELISA according to manufacturer’s protocol.

Techniques: Clinical Proteomics, Comparison, Control, MANN-WHITNEY

Journal: BMJ Open Respiratory Research

Article Title: Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome

doi: 10.1136/bmjresp-2025-003630

Figure Lengend Snippet: Correlation matrix of plasma sRAGE and Ang-2 with age, PIM 3 score, PELOD2 score and the oxygenation index. Spearman test was used to assess correlation. Numbers in cells refer to Spearman’s correlation coefficient. *p<0.05, **p<0.01, ***p<0.001. Ang-2, angiopoietin-2; PELOD 2, Pediatric Logistic Organ Dysfunction 2 score; PIM 3, Pediatric Index of Mortality 3 score; sRAGE, soluble receptor for advanced glycation end-products.

Article Snippet: The plasma was then aspirated and stored at −80°C for later batched analysis. sRAGE (R&D Systems; catalogue no. DY1145) and Ang-2 (R&D Systems; catalogue no. DY623) were measured in duplicate using an ELISA according to manufacturer’s protocol.

Techniques: Clinical Proteomics

Journal: BMJ Open Respiratory Research

Article Title: Validation of plasma soluble receptor of advanced glycation end-products and angiopoietin-2 in paediatric acute respiratory distress syndrome

doi: 10.1136/bmjresp-2025-003630

Figure Lengend Snippet: Plasma sRAGE and Ang-2 levels in the presence of cardiovascular dysfunction, multiorgan dysfunction and mortality. Data presented as median (IQR), and comparison was made using the Mann-Whitney test. Organ dysfunctions were defined according to the International Pediatric Sepsis Consensus Conference. Ang-2, angiopoietin-2; ICU, intensive care unit; sRAGE, soluble receptor for advanced glycation end-products.

Article Snippet: The plasma was then aspirated and stored at −80°C for later batched analysis. sRAGE (R&D Systems; catalogue no. DY1145) and Ang-2 (R&D Systems; catalogue no. DY623) were measured in duplicate using an ELISA according to manufacturer’s protocol.

Techniques: Clinical Proteomics, Comparison, MANN-WHITNEY

Journal: Physiological Reports

Article Title: Biological sex modulates lung injury severity in adolescent mice exposed to short‐term aerosolized vitamin E acetate

doi: 10.14814/phy2.70691

Figure Lengend Snippet: Serum sRAGE concentration (ng/mL) in the BALF supernatant was measured using ELISA. 3‐day and 10‐day VEA‐exposed males and females displayed significantly higher serum sRAGE levels compared to control groups. Additionally, 3‐day and 10‐day VEA‐exposed females presented with significantly higher sRAGE levels when compared to their male counterparts. Column height represents mean concentration ± standard error (SE). N = 6/treatment group. BALF, bronchoalveolar lavage fluid; sRAGE, soluble receptor of advanced glycation end products; VEA, vitamin E acetate.

Article Snippet: Serum sRAGE levels were quantified using the murine sRAGE Quantikine ELISA kit (Cat. NO. MRG00, R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Control

Journal: medRxiv

Article Title: Aerobic Exercise Training Elevates Circulating sRAGE via Modulation of Sheddase Regulation in Adults with Type 2 Diabetes

doi: 10.1101/2025.09.10.25335517

Figure Lengend Snippet: Basal solubilized receptor for advanced glycation end products (sRAGE; A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).

Article Snippet: sRAGE was quantified via sRAGE ELISA (DRG000, R&D Systems, Minneapolis, MN) according to manufacturer’s instructions.

Techniques: Control, Two Tailed Test

Journal: Biomedicines

Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

doi: 10.3390/biomedicines13020438

Figure Lengend Snippet: Plasma concentrations of AGEs ( A ), sRAGE ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.

Article Snippet: Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction.

Techniques: Clinical Proteomics, MANN-WHITNEY

Journal: Biomedicines

Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

doi: 10.3390/biomedicines13020438

Figure Lengend Snippet: Correlations of AGE and sRAGE with vascular markers in neuropathic patients before and after ALA treatment.

Article Snippet: Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction.

Techniques: